Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia

被引：1

作者：

Piccaluga, PP

Luatti, S

Ascani, S

Bianchini, M

Malagola, M

Rondoni, M

Gaitani, S

Testoni, N

Pileri, SA

Baccarani, M

Martinelli, G

Visani, G

机构：

[1] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA

[2] Univ Bologna, L & A Seragnoli S Orsola Malpighi Hosp, I-40138 Bologna, Italy

[3] San Salvatore Hosp, Dept Hematol, I-61100 Pesaro, Italy

来源：

CANCER GENETICS AND CYTOGENETICS | 2004年 / 151卷 / 01期

关键词：

D O I：

10.1016/j.cancergencyto.2003.08.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：85 / 86

页数：2

共 9 条

[1] Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state [J].

Bounamici, S ;

Ottaviani, E ;

Testoni, N ;

Montefusco, V ;

Visani, G ;

Bonifazi, F ;

Amabile, M ;

Terragna, C ;

Ruggeri, D ;

Piccaluga, PP ;

Isidori, A ;

Malagola, M ;

Baccarani, M ;

Tura, S ;

Martinelli, G .

BLOOD, 2002, 99 (02) :443-449

[2] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[3]

Dessen P, CHROMOSOME ATLAS GEN

[4] Perspectives on the development of a molecularly targeted agent [J].

Druker, BJ .

CANCER CELL, 2002, 1 (01) :31-36

[5] Risk-adapted treatment according to minimal residual disease in adult ALL [J].

Gökbuget, N ;

Kneba, M ;

Raff, T ;

Bruggemann, M ;

Scheuring, U ;

Reutzel, R ;

Hoelzer, D .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (04) :639-652

[6] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].

Grimwade, D ;

Walker, H ;

Oliver, F ;

Wheatley, K ;

Harrison, C ;

Harrison, G ;

Rees, J ;

Hann, I ;

Stevens, R ;

Burnett, A ;

Goldstone, A .

BLOOD, 1998, 92 (07) :2322-2333

[7] Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia [J].

Grimwade, D ;

Lo Coco, F .

LEUKEMIA, 2002, 16 (10) :1959-1973

[8]

Huret JL, ATLAS GENET CYTOGENE

[9]

KARGER S, 1995, ISCN GUID CANC CYT I

← 1 →